These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 25202327)

  • 1. Effects of recombinant human thyrotropin administration on 24-hour arterial pressure in female undergoing evaluation for differentiated thyroid cancer.
    Rentziou G; Saltiki K; Manios E; Stamatelopoulos K; Koroboki E; Vemmou A; Mantzou E; Zakopoulos N; Alevizaki M
    Int J Endocrinol; 2014; 2014():270213. PubMed ID: 25202327
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recombinant Human Thyrotropin Improves Endothelial Coronary Flow Reserve in Thyroidectomized Patients with Differentiated Thyroid Cancer.
    Ippolito S; Ippolito R; Peirce C; Esposito R; Arpaia D; Santoro C; Pontieri G; Cocozza S; Galderisi M; Biondi B
    Thyroid; 2016 Nov; 26(11):1528-1534. PubMed ID: 27558484
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recombinant human TSH modulates in vivo C-telopeptides of type-1 collagen and bone alkaline phosphatase, but not osteoprotegerin production in postmenopausal women monitored for differentiated thyroid carcinoma.
    Mazziotti G; Sorvillo F; Piscopo M; Cioffi M; Pilla P; Biondi B; Iorio S; Giustina A; Amato G; Carella C
    J Bone Miner Res; 2005 Mar; 20(3):480-6. PubMed ID: 15746993
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A high normal thyroid-stimulating hormone is associated with arterial stiffness, central systolic blood pressure, and 24-hour systolic blood pressure in males with treatment-naïve hypertension and euthyroid.
    Kwon BJ; Roh JW; Lee SH; Lim SM; Park CS; Kim DB; Jang SW; Chang K; Kim HY; Ihm SH
    Int J Cardiol; 2014 Dec; 177(3):949-56. PubMed ID: 25449506
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Age influences TSH serum levels after withdrawal of l-thyroxine or rhTSH stimulation in patients affected by differentiated thyroid cancer.
    Montesano T; Durante C; Attard M; Crocetti U; Meringolo D; Bruno R; Tumino S; Rubello D; Al-Nahhas A; Colandrea M; Maranghi M; Travascio L; Ronga G; Torlontano M
    Biomed Pharmacother; 2007 Sep; 61(8):468-71. PubMed ID: 17553654
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The diagnostic use of the rhTSH/thyroglobulin test in differentiated thyroid cancer patients with persistent disease and low thyroglobulin levels.
    Pellegriti G; Scollo C; Regalbuto C; Attard M; Marozzi P; Vermiglio F; Violi MA; Cianci M; Vigneri R; Pezzino V; Squatrito S
    Clin Endocrinol (Oxf); 2003 May; 58(5):556-61. PubMed ID: 12699436
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Absence of thyrotropin-induced increase in leptin levels in patients with history of differentiated thyroid carcinoma undergoing recombinant human thyrotropin testing.
    Cecoli F; Andraghetti G; Ghiara C; Briatore L; Cavallero D; Mussap M; Minuto F; Giusti M
    J Endocrinol Invest; 2008 Oct; 31(10):888-92. PubMed ID: 19092294
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Examining recombinant human TSH primed ¹³¹I therapy protocol in patients with metastatic differentiated thyroid carcinoma: comparison with the traditional thyroid hormone withdrawal protocol.
    Rani D; Kaisar S; Awasare S; Kamaldeep ; Abhyankar A; Basu S
    Eur J Nucl Med Mol Imaging; 2014 Sep; 41(9):1767-80. PubMed ID: 24687139
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Age and body composition influence TSH concentrations after administration of rhTSH.
    Holthausen FF; von Müller F; Happel C; Kranert WT; Grünwald F
    Nuklearmedizin; 2015; 54(1):20-5. PubMed ID: 25566749
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recombinant human thyroid stimulating hormone does not acutely change serum osteoprotegerin and soluble receptor activator of nuclear factor-kappaBeta ligand in patients under evaluation for differentiated thyroid carcinoma.
    Giusti M; Cecoli F; Ghiara C; Rubinacci A; Villa I; Cavallero D; Mazzuoli L; Mussap M; Lanzi R; Minuto F
    Hormones (Athens); 2007; 6(4):304-13. PubMed ID: 18055421
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of Clinical Factors for the Determination of Optimal Serum Level of Thyrotropin After Recombinant Human Thyroid-Stimulating Hormone Administration.
    Son SH; Lee SW; Jung JH; Kim CY; Kim DH; Jeong SY; Ahn BC; Lee J
    Nucl Med Mol Imaging; 2015 Dec; 49(4):268-75. PubMed ID: 26550045
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum Basal thyroglobulin measured by a second-generation assay correlates with the recombinant human thyrotropin-stimulated thyroglobulin response in patients treated for differentiated thyroid cancer.
    Spencer C; Fatemi S; Singer P; Nicoloff J; Lopresti J
    Thyroid; 2010 Jun; 20(6):587-95. PubMed ID: 20470203
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diagnostic use of recombinant human thyrotropin in patients with thyroid carcinoma (phase I/II study).
    Meier CA; Braverman LE; Ebner SA; Veronikis I; Daniels GH; Ross DS; Deraska DJ; Davies TF; Valentine M; DeGroot LJ
    J Clin Endocrinol Metab; 1994 Jan; 78(1):188-96. PubMed ID: 8288703
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of GH replacement on 24-h ambulatory blood pressure and its circadian rhythm in adult GH deficiency.
    Ahmad AM; Hopkins MT; Weston PJ; Fraser WD; Vora JP
    Clin Endocrinol (Oxf); 2002 Apr; 56(4):431-7. PubMed ID: 11966735
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Does recombinant human thyrotropin-stimulated positron emission tomography with [18F]fluoro-2-deoxy-D-glucose improve detection of recurrence of well-differentiated thyroid carcinoma in patients with low serum thyroglobulin?
    Vera P; Kuhn-Lansoy C; Edet-Sanson A; Hapdey S; Modzelewski R; Hitzel A; d'Anjou J; Basuyau JP
    Thyroid; 2010 Jan; 20(1):15-23. PubMed ID: 20017617
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum thyrotropin (TSH) levels after recombinant human TSH injections in children and teenagers with papillary thyroid cancer.
    Iorcansky S; Herzovich V; Qualey RR; Tuttle RM
    J Clin Endocrinol Metab; 2005 Dec; 90(12):6553-5. PubMed ID: 16174712
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recombinant thyrotropin use in children and adolescents with differentiated thyroid cancer: a multicenter retrospective study.
    Luster M; Handkiewicz-Junak D; Grossi A; Zacharin M; Taïeb D; Cruz O; Hitzel A; Casas JA; Mäder U; Dottorini ME;
    J Clin Endocrinol Metab; 2009 Oct; 94(10):3948-53. PubMed ID: 19773393
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ablation of thyroid residues with 30 mCi (131)I: a comparison in thyroid cancer patients prepared with recombinant human TSH or thyroid hormone withdrawal.
    Pacini F; Molinaro E; Castagna MG; Lippi F; Ceccarelli C; Agate L; Elisei R; Pinchera A
    J Clin Endocrinol Metab; 2002 Sep; 87(9):4063-8. PubMed ID: 12213846
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recombinant human thyrotropin is helpful in the follow-up and 131I therapy of patients with thyroid cancer: a report of the results and benefits using recombinant human thyrotropin in clinical routine.
    Kohlfuerst S; Igerc I; Lind P
    Thyroid; 2005 Apr; 15(4):371-6. PubMed ID: 15876162
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Assessment of recombinant human thyrotropin application in following-up patients with well-differentiated thyroid carcinoma].
    Rajkovaca Z; Kovacević P; Stanetić M; Ristić S
    Vojnosanit Pregl; 2012 Nov; 69(11):941-6. PubMed ID: 23311243
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.